Latus Bio
Gene therapy for CNS diseases
About
Latus Bio is a biotechnology company developing pioneering AAV-mediated gene therapies targeting genetically-defined central nervous system (CNS) disorders such as Huntington's disease and CLN2 disease. Founded to leverage proprietary technology platforms, Latus aims to transform treatments for large rare and common CNS disorders. Their lead programs include LTS-201 for Huntington's disease and therapies for CLN2, focusing on knocking down disease drivers. With a strong Series A funding of $97M, the company is advancing preclinical development toward IND submissions and first-in-human trials by 2025-2026. The business model centers on innovation and clinical development of gene therapy candidates, backed by prominent investors to accelerate pipeline progress.
Products
-
gene therapy platform
— Delivers gene therapies targeting specific cell types and tissues to treat genetic diseases with improved safety and lower doses.
Customer sectors: biopharma researchers, gene therapy developers, translational medicine
Market research & competitive positioning
Source-backed TAM / SAM / SOM sizing, displacement analysis, and an interactive peer positioning map for Latus Bio — available to members.
